OncoMatch/Clinical Trials/NCT07206498
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Is NCT07206498 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Osimertinib (Tagrisso®) and WSD0922-FU for non small cell lung cancer (nsclc).
Treatment: Osimertinib (Tagrisso®) · WSD0922-FU — This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR sensitive mutation
Patients who have been genetically tested to carry EGFR sensitive mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Received chemotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: radiotherapy
Received radiotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: biological therapy
Received biological therapy...within 4 weeks before the first administration of the study drug
Cannot have received: targeted therapy
Received targeted therapy...within 4 weeks before the first administration of the study drug
Cannot have received: endocrine therapy
Received endocrine therapy...within 4 weeks before the first administration of the study drug
Cannot have received: immunotherapy
Received immunotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: anti-tumor drug treatments
Received...other anti-tumor drug treatments within 4 weeks before the first administration of the study drug
Cannot have received: EGFR tyrosine kinase inhibitor
Exception: more than two EGFR-TKI inhibitors for part A
Have previously received more than two EGFR-TKI inhibitors for part A
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify